Developer docs
API playgroundTry for free, no card

Search company profiles

OpenBench

Full company profile

uuid0009x1l

Namestring
OpenBench
Legal namestring
OpenBench, Inc.
Websiteurl
openbench.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

OpenBench, Inc. is a US-based, privately held AI-driven drug discovery company headquartered at 535 Mission Street, Floor 14, San Francisco. The company has operated since 2019 with a headcount of 1–10 employees and describes itself as the only fee-for-success contract research organization in drug discovery. Its core offering is an AI-enabled structure-based virtual screening platform that screens billions to trillions of compounds against client-provided or modeled target structures, with structural enablement spanning homology modeling, molecular dynamics, and AlphaFold2-based prediction for targets lacking crystal structures. The platform is positioned to drug first-in-class targets (over 50% of binding sites worked on reportedly have no specific small molecule prior art) and to prosecute challenging modalities such as allosteric sites and non-functional binding sites, with the company claiming a 90% success rate on commercial projects to date.

The business model is outcome-based: OpenBench funds all upfront discovery costs (virtual screening, compound acquisition, confirmatory assaying) and only charges a success fee upon delivery of validated hit series meeting predefined client criteria; clients purchase IP outright with no continuing royalty or milestone obligations. Standard engagement terms include 10-year exclusivity on purchased compounds and up to 5 years of flexible exclusivity on disease targets. Services are sold via direct partnership agreements, supplemented by a strategic CRO partnership with Concept Life Sciences (May 2026) for bundled chemistry/in-vitro delivery, an extended collaboration with Enamine for compound library access, and a Scientist.com marketplace listing. Customers span early-stage oncology and rare-disease biotechs (HemoShear, Tavros, OnKure, 858 Therapeutics, ORIC, Volastra, Related Sciences) and extend to mid-to-late stage biotechs (Brii Biosciences) and academic institutions (UNC Chapel Hill). The company is co-founded by James Yoder (CEO) and Jim Thompson (COO), with Lewis Martin, PhD serving as Chief Scientific Officer.

Short descriptiontext

OpenBench is a US-based AI-driven drug discovery company that uses structure-based virtual screening to identify validated hit series for early-stage biotechs. The firm operates a fee-for-success model in which it funds upfront discovery costs and only charges upon delivery of compounds meeting client-defined criteria.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, virtual screening, hit identification, structure-based screening, small molecule discovery
Industry1 code
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
AI Drug Discovery Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Fee-for-Success Hit Discovery Services
TypeUsage Based
Description

OpenBench operates a success-based fee model where they fund all upfront discovery costs (virtual screening, hit acquisition, confirmatory assaying) and only charge clients when validated hit series meeting predefined criteria are delivered. Clients purchase IP outright upon project completion with no continuing obligation for milestones or royalties.

openbench.com
2Strategic Partnership Services
TypeUsage Based
Description

Partnership with Concept Life Sciences enables delivery of integrated drug discovery services combining OpenBench's AI virtual screening with medicinal chemistry and in-vitro testing, with success-based pricing.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Fee-for-success model - only pay for validated hits
ModelOutcome Based/ PerformanceBilling cadencePay-as-you-go
Notes

OpenBench funds all upfront discovery activities including virtual screening, compound acquisition, and confirmatory assaying. Clients only pay a success fee upon delivery of validated hit series that meet predefined criteria. IP is purchased outright with no continuing royalties or milestones.

openbench.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

OpenBench provides fee-for-success small molecule hit discovery services powered by an AI-enabled structure-based virtual screening platform that screens billions to trillions of compounds against client or modeled target structures. The company funds all upfront discovery costs and only charges clients upon delivery of validated, medicinal-chemistry-approved hit series meeting predefined success criteria, transferring compound IP outright with no royalties or milestones.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 90% success rate on commercial projects completed to-date
+3 more records
Product overview1 text field

OpenBench offers a single unified success-driven drug discovery service centered on its AI-enabled structure-based virtual screening platform. The platform screens billions to trillions of compounds virtually against client-provided or modeled target structures, delivering validated hit series within approximately six months. Under the fee-for-success model, OpenBench absorbs all upfront discovery costs and only charges upon delivery of validated hits meeting client-defined criteria. The company partners with clients' preferred CROs and assay systems rather than operating internal chemistry labs.

Product and service1 record
1AI-Enabled Structure-Based Virtual Screening Platform (Fee-for-Success Hit Discovery)
CategoryAI drug discovery / contract research services
Description

Success-driven hit discovery service in which OpenBench funds all upfront discovery costs and uses its AI-enabled structure-based virtual screening platform to screen billions to trillions of compounds against client-provided or modeled target structures, delivering validated, medicinal-chemistry-approved hit series only upon meeting predefined success criteria. Intended for biotech and pharmaceutical partners seeking early-stage drug discovery, hit identification, and entry points for medicinal chemistry programs.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-21
Description

Strategic partnership to deliver success-based drug discovery services for early-stage biotech companies. Combines OpenBench's AI-based virtual screening platform with Concept Life Sciences' medicinal chemistry and in-vitro testing capabilities. Under the fee-for-success model, OpenBench funds all upfront discovery costs and charges only upon delivery of validated hit series. Collaboration aims to guide clients from target to validated hit series within six months.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-12-11
Description

AI-driven collaboration leveraging OpenBench's proprietary structure-based AI platform for drug discovery. Brii Bio gains exclusive rights to new leads and access to OpenBench's screening technology to accelerate discovery efforts and advance proprietary technology for new discovery efforts.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-11-04
Description

Collaboration to discover small molecule inhibitors using OpenBench's structure-based machine learning platform. Focus initially on an undisclosed target nominated by 858 Therapeutics.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-09-17
Description

Collaboration to apply OpenBench's success-driven discovery approach and structure-based machine learning platform to enrich early discovery efforts against an undisclosed target identified by ORIC's resistance platform to target cancer-specific vulnerabilities.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-06-03
Description

OpenBench assigned a library of promising lead compounds to OnKure, a clinical-stage biopharmaceutical company focused on novel precision medicines in oncology, to advance pursuit of an important precision oncology target.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-06-06
Description

Success-driven collaboration to leverage OpenBench's structure-based machine learning platform to find novel, potent chemical hit material for an initial high value target nominated by Related Sciences.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-04-27
Description

Expanded strategic collaboration to discover small molecule modulators of up to five oncology targets across an initial 18-month term. Tavros is a precision oncology platform company exploiting tumors' genetic vulnerabilities.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2023-03-06
Description

Extended collaboration with the world's leading provider of compounds for biological screening. Partnership enriches global early discovery efforts by combining OpenBench's virtual screening with Enamine's REAL compound library.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-11-09
Description

Partnership with UNC's Office of the Vice Chancellor for Research and Office of Technology Commercialization focused on high-value oncology targets identified by researchers at the University.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-10-18
Description

Success-driven collaboration where OpenBench discovered novel, potent small molecule antagonists to enrich Volastra's early discovery efforts against an undisclosed cancer target. Volastra focuses on exploiting chromosomal instability to treat cancer.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-06-07
Description

OpenBench agreed to assign ownership of two promising chemical series to HemoShear Therapeutics, a clinical stage biotechnology company, to advance HemoShear's pursuit of an undisclosed rare disease target.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-12-02
Description

Initial collaboration where OpenBench identified novel, potent antagonists against an undisclosed cancer target identified by Tavros's proprietary functional genomics platform.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-10-05
Description

Agreement to use the OpenBench virtual screening platform to identify novel, potent inhibitors of an undisclosed rare disease target.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

OpenBench is listed as a Registered Supplier on Scientist.com marketplace, providing visibility to biotech companies seeking discovery services.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Schrödinger operates an industry-leading computational chemistry and structure-based drug design platform that competes directly with OpenBench in virtual screening and hit identification for pharma and biotech partners.

TypeDirect peer
Description

Atomwise is an AI-driven structure-based virtual screening company focused on small molecule hit discovery through partnerships with pharma and biotech, closely overlapping OpenBench's core offering.

TypeDirect peer
Description

Insilico Medicine applies generative AI and structure-based methods across hit ID, lead generation, and beyond, competing with OpenBench for biotech discovery collaborations and partnerships.

TypeBroad incumbent
Description

Exscientia is an established AI drug discovery company offering an end-to-end platform spanning design through clinical, overlapping OpenBench's hit discovery capabilities as part of a broader pipeline and partnership model.

TypeBroad incumbent
Description

Recursion is a large, publicly listed AI-driven biotech combining high-throughput biology with computational methods; it overlaps with OpenBench in target prioritization and early discovery partnerships with pharma.

6Iambic Therapeutics
TypeEmerging player
Description

Iambic Therapeutics uses AI-driven structure-based methods for small molecule discovery, with comparable focus on hard and novel targets similar to OpenBench's first-in-class emphasis.

TypeBroad incumbent
Description

XtalPi operates an AI plus robotics-enabled drug discovery platform covering hit identification through solid-form development, overlapping OpenBench in AI-driven virtual screening for pharma partners.

8Isomorphic Labs
TypeBroad incumbent
Description

Isomorphic Labs is Alphabet-backed and applies AI to structure-based drug design and discovery, directly comparable to OpenBench's structure-based virtual screening approach at much greater scale and capitalization.

TypeOthers
Description

Enamine is a global supplier of screening compounds (including the REAL database) and an active partner of OpenBench, providing compound libraries that enable OpenBench's trillion-scale virtual screens and downstream confirmatory testing.

TypeOthers
Description

Concept Life Sciences is an integrated drug discovery CRO partner of OpenBench providing medicinal chemistry and in-vitro testing, enabling delivery of OpenBench's fee-for-success end-to-end hit discovery collaborations.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OpenBench

AI Drug Discovery Servicesopenbench.com

OpenBench is a US-based AI-driven drug discovery company that uses structure-based virtual screening to identify validated hit series for early-stage biotechs. The firm operates a fee-for-success model in which it funds upfront discovery costs and only charges upon delivery of compounds meeting client-defined criteria.

What OpenBench does

OpenBench, Inc. is a US-based, privately held AI-driven drug discovery company headquartered at 535 Mission Street, Floor 14, San Francisco. The company has operated since 2019 with a headcount of 1–10 employees and describes itself as the only fee-for-success contract research organization in drug discovery. Its core offering is an AI-enabled structure-based virtual screening platform that screens billions to trillions of compounds against client-provided or modeled target structures, with structural enablement spanning homology modeling, molecular dynamics, and AlphaFold2-based prediction for targets lacking crystal structures. The platform is positioned to drug first-in-class targets (over 50% of binding sites worked on reportedly have no specific small molecule prior art) and to prosecute challenging modalities such as allosteric sites and non-functional binding sites, with the company claiming a 90% success rate on commercial projects to date.

The business model is outcome-based: OpenBench funds all upfront discovery costs (virtual screening, compound acquisition, confirmatory assaying) and only charges a success fee upon delivery of validated hit series meeting predefined client criteria; clients purchase IP outright with no continuing royalty or milestone obligations. Standard engagement terms include 10-year exclusivity on purchased compounds and up to 5 years of flexible exclusivity on disease targets. Services are sold via direct partnership agreements, supplemented by a strategic CRO partnership with Concept Life Sciences (May 2026) for bundled chemistry/in-vitro delivery, an extended collaboration with Enamine for compound library access, and a Scientist.com marketplace listing. Customers span early-stage oncology and rare-disease biotechs (HemoShear, Tavros, OnKure, 858 Therapeutics, ORIC, Volastra, Related Sciences) and extend to mid-to-late stage biotechs (Brii Biosciences) and academic institutions (UNC Chapel Hill). The company is co-founded by James Yoder (CEO) and Jim Thompson (COO), with Lewis Martin, PhD serving as Chief Scientific Officer.

OpenBench firmographics

Firmographics
Name
OpenBench
Legal name
OpenBench, Inc.
Website
https://openbench.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
OpenBench is a US-based AI-driven drug discovery company that uses structure-based virtual screening to identify validated hit series for early-stage biotechs. The firm operates a fee-for-success model in which it funds upfront discovery costs and only charges upon delivery of compounds meeting client-defined criteria.
Ownership category
akta.pro rank

OpenBench industry classification

Industry
Product category
AI Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • AI drug discovery
  • Virtual screening
  • Hit identification
  • Structure-based screening
  • Small molecule discovery

Where OpenBench is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

OpenBench business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Fee-for-Success Hit Discovery Services: OpenBench operates a success-based fee model where they fund all upfront discovery costs (virtual screening, hit acquisition, confirmatory assaying) and only charge clients when validated hit series meeting predefined criteria are delivered. Clients purchase IP outright upon project completion with no continuing obligation for milestones or royalties.
  2. Strategic Partnership Services: Partnership with Concept Life Sciences enables delivery of integrated drug discovery services combining OpenBench's AI virtual screening with medicinal chemistry and in-vitro testing, with success-based pricing.

Pricing tiers

ModelBillingPrice
Outcome Based/ PerformancePay-as-you-goFee-for-success model - only pay for validated hits

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

OpenBench product offering

Product offering

Core offering

OpenBench provides fee-for-success small molecule hit discovery services powered by an AI-enabled structure-based virtual screening platform that screens billions to trillions of compounds against client or modeled target structures. The company funds all upfront discovery costs and only charges clients upon delivery of validated, medicinal-chemistry-approved hit series meeting predefined success criteria, transferring compound IP outright with no royalties or milestones.

Product overview

OpenBench offers a single unified success-driven drug discovery service centered on its AI-enabled structure-based virtual screening platform. The platform screens billions to trillions of compounds virtually against client-provided or modeled target structures, delivering validated hit series within approximately six months. Under the fee-for-success model, OpenBench absorbs all upfront discovery costs and only charges upon delivery of validated hits meeting client-defined criteria. The company partners with clients' preferred CROs and assay systems rather than operating internal chemistry labs.

Differentiator

Problem solved

Functional benefit

Products and services

  • AI-Enabled Structure-Based Virtual Screening Platform (Fee-for-Success Hit Discovery) Success-driven hit discovery service in which OpenBench funds all upfront discovery costs and uses its AI-enabled structure-based virtual screening platform to screen billions to trillions of compounds against client-provided or modeled target structures, delivering validated, medicinal-chemistry-approved hit series only upon meeting predefined success criteria. Intended for biotech and pharmaceutical partners seeking early-stage drug discovery, hit identification, and entry points for medicinal chemistry programs.

Quantifiable outcome

  • 90% success rate on commercial projects completed to-date
  • +3 more outcomes

Companies that use OpenBench

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

OpenBench technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

OpenBench partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core, major and minor.

  • Concept Life SciencescoreStrategic or Co-development Partner · 21 May 2026Strategic partnership to deliver success-based drug discovery services for early-stage biotech companies. Combines OpenBench's AI-based virtual screening platform with Concept Life Sciences' medicinal chemistry and in-vitro testing capabilities. Under the fee-for-success model, OpenBench funds all upfront discovery costs and charges only upon delivery of validated hit series. Collaboration aims to guide clients from target to validated hit series within six months.
  • Brii BiosciencesmajorStrategic or Co-development Partner · 11 December 2025AI-driven collaboration leveraging OpenBench's proprietary structure-based AI platform for drug discovery. Brii Bio gains exclusive rights to new leads and access to OpenBench's screening technology to accelerate discovery efforts and advance proprietary technology for new discovery efforts.
  • 858 TherapeuticsmajorStrategic or Co-development Partner · 4 November 2024Collaboration to discover small molecule inhibitors using OpenBench's structure-based machine learning platform. Focus initially on an undisclosed target nominated by 858 Therapeutics.
  • ORIC PharmaceuticalsmajorStrategic or Co-development Partner · 17 September 2024Collaboration to apply OpenBench's success-driven discovery approach and structure-based machine learning platform to enrich early discovery efforts against an undisclosed target identified by ORIC's resistance platform to target cancer-specific vulnerabilities.
  • OnKure TherapeuticsmajorStrategic or Co-development Partner · 3 June 2024OpenBench assigned a library of promising lead compounds to OnKure, a clinical-stage biopharmaceutical company focused on novel precision medicines in oncology, to advance pursuit of an important precision oncology target.
  • Related SciencesmajorStrategic or Co-development Partner · 6 June 2023Success-driven collaboration to leverage OpenBench's structure-based machine learning platform to find novel, potent chemical hit material for an initial high value target nominated by Related Sciences.
  • Tavros TherapeuticscoreStrategic or Co-development Partner · 27 April 2023Expanded strategic collaboration to discover small molecule modulators of up to five oncology targets across an initial 18-month term. Tavros is a precision oncology platform company exploiting tumors' genetic vulnerabilities.
  • EnaminemajorTechnology or Integration · 6 March 2023Extended collaboration with the world's leading provider of compounds for biological screening. Partnership enriches global early discovery efforts by combining OpenBench's virtual screening with Enamine's REAL compound library.
  • University of North Carolina at Chapel HillmajorStrategic or Co-development Partner · 9 November 2022Partnership with UNC's Office of the Vice Chancellor for Research and Office of Technology Commercialization focused on high-value oncology targets identified by researchers at the University.
  • Volastra TherapeuticsmajorStrategic or Co-development Partner · 18 October 2022Success-driven collaboration where OpenBench discovered novel, potent small molecule antagonists to enrich Volastra's early discovery efforts against an undisclosed cancer target. Volastra focuses on exploiting chromosomal instability to treat cancer.
  • HemoShear TherapeuticsmajorStrategic or Co-development Partner · 7 June 2022OpenBench agreed to assign ownership of two promising chemical series to HemoShear Therapeutics, a clinical stage biotechnology company, to advance HemoShear's pursuit of an undisclosed rare disease target.
  • Tavros TherapeuticsmajorStrategic or Co-development Partner · 2 December 2021Initial collaboration where OpenBench identified novel, potent antagonists against an undisclosed cancer target identified by Tavros's proprietary functional genomics platform.
  • HemoShear TherapeuticsmajorStrategic or Co-development Partner · 5 October 2021Agreement to use the OpenBench virtual screening platform to identify novel, potent inhibitors of an undisclosed rare disease target.
  • Scientist.comminorChannel Partner/ Reseller/ DistributorOpenBench is listed as a Registered Supplier on Scientist.com marketplace, providing visibility to biotech companies seeking discovery services.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

OpenBench competitors and assessment

Company assessment

Direct peers

  • Schrödinger: Schrödinger operates an industry-leading computational chemistry and structure-based drug design platform that competes directly with OpenBench in virtual screening and hit identification for pharma and biotech partners.
  • Atomwise: Atomwise is an AI-driven structure-based virtual screening company focused on small molecule hit discovery through partnerships with pharma and biotech, closely overlapping OpenBench's core offering.
  • Insilico Medicine: Insilico Medicine applies generative AI and structure-based methods across hit ID, lead generation, and beyond, competing with OpenBench for biotech discovery collaborations and partnerships.

Broad incumbents

  • Exscientia: Exscientia is an established AI drug discovery company offering an end-to-end platform spanning design through clinical, overlapping OpenBench's hit discovery capabilities as part of a broader pipeline and partnership model.
  • Recursion: Recursion is a large, publicly listed AI-driven biotech combining high-throughput biology with computational methods; it overlaps with OpenBench in target prioritization and early discovery partnerships with pharma.
  • XtalPi: XtalPi operates an AI plus robotics-enabled drug discovery platform covering hit identification through solid-form development, overlapping OpenBench in AI-driven virtual screening for pharma partners.
  • Isomorphic Labs: Isomorphic Labs is Alphabet-backed and applies AI to structure-based drug design and discovery, directly comparable to OpenBench's structure-based virtual screening approach at much greater scale and capitalization.

Emerging players

  • Iambic Therapeutics: Iambic Therapeutics uses AI-driven structure-based methods for small molecule discovery, with comparable focus on hard and novel targets similar to OpenBench's first-in-class emphasis.

Others

  • Enamine: Enamine is a global supplier of screening compounds (including the REAL database) and an active partner of OpenBench, providing compound libraries that enable OpenBench's trillion-scale virtual screens and downstream confirmatory testing.
  • Concept Life Sciences: Concept Life Sciences is an integrated drug discovery CRO partner of OpenBench providing medicinal chemistry and in-vitro testing, enabling delivery of OpenBench's fee-for-success end-to-end hit discovery collaborations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

OpenBench social profiles

Digital presence

OpenBench compliance and trust

Trust signal

Compliance2 records

OpenBench financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OpenBench leadership team

Management profile

Number of profiles

Profiles5 records

OpenBench funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OpenBench M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OpenBench

What does OpenBench do?

OpenBench provides fee-for-success small molecule hit discovery services powered by an AI-enabled structure-based virtual screening platform that screens billions to trillions of compounds against client or modeled target structures. The company funds all upfront discovery costs and only charges clients upon delivery of validated, medicinal-chemistry-approved hit series meeting predefined success criteria, transferring compound IP outright with no royalties or milestones.

Is OpenBench a public or private company?

OpenBench is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was OpenBench founded?

OpenBench was founded in 2019. It employs 1 to 10 people.

Where is OpenBench based?

OpenBench is headquartered in San Francisco, United States, in the North America region.

How does OpenBench make money?

Two revenue lines are on record. Fee-for-Success Hit Discovery Services are the primary driver. The others are strategic Partnership Services.

Who are OpenBench's main competitors?

Direct peers on record are Schrödinger, Atomwise and Insilico Medicine. Broad incumbents are Exscientia, Recursion, XtalPi and Isomorphic Labs. Iambic Therapeutics is listed as an emerging player. Others are Enamine and Concept Life Sciences.

Does OpenBench have an API?

No public API is recorded for OpenBench.

What industry is OpenBench in?

OpenBench's product category is AI Drug Discovery Services. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceNovalix and OpenBench Partner to Create Fee-For-Success Drug Discovery for Life Science OrganizationsNovalix and OpenBench announced a partnership to deliver experimentally validated chemical hit series via a fee-for-success model. OpenBench screens compounds and synthesizes hits, while Novalix performs in vitro screening, with clients paying only when validated hits are delivered. The workflow can deliver validated hit series in as little as six months.Pharmaceutical Business reviewConcept Life Sciences, OpenBench partner on drug discovery servicesConcept Life Sciences has signed a strategic partnership with OpenBench to deliver success-based drug discovery services for early-stage biotech companies. The collaboration combines OpenBench's AI-based virtual screening platform with Concept Life Sciences' medicinal chemistry and in-vitro testing capabilities, with OpenBench bearing initial discovery costs and charging only upon delivery of validated hits. The partnership aims to guide clients from target to validated hit series within six months, offering a capital-efficient alternative to traditional R&D models amid current biotech funding constraints.The Times of IndiaAI-powered drug discovery partnership aims to accelerate biotech innovationConcept Life Sciences and OpenBench launched a joint AI-driven hit discovery platform for biotechs, using a fee-for-success model where OpenBench covers virtual screening and lab validation costs upfront. The partnership aims to deliver validated chemical hits in as little as six months, addressing high upfront costs and selective venture funding in biotech.YahooConcept Life Sciences and OpenBench partner on drug discovery servicesConcept Life Sciences has signed a strategic partnership with OpenBench to deliver success-based drug discovery services for early-stage biotech companies, combining OpenBench's AI-based virtual screening platform with Concept Life Sciences' medicinal chemistry and in-vitro capabilities. Under the fee-for-success model, OpenBench absorbs initial discovery costs and only charges clients once validated hits are delivered, shifting scientific and financial risk away from biotech customers. The collaboration aims to guide clients from target to validated hit series within six months, offering a capital-efficient alternative amid current biotech funding constraints.The Manila TimesConcept Life Sciences Partners with OpenBench to Deliver Success-Based Drug Discovery Services for Early-Stage BiotechConcept Life Sciences and OpenBench announced a strategic partnership to provide success-based drug discovery services for early-stage biotech companies, combining OpenBench's AI-driven virtual screening platform with Concept Life Sciences' medicinal chemistry and in-vitro testing capabilities. Under the model, OpenBench covers all upfront discovery costs and only charges a success-based fee upon delivery of validated hit compounds, enabling clients to progress from target to validated hit series in as little as six months at zero upfront cost. The partnership addresses constrained biotech funding by offering a capital-efficient alternative to traditional discovery models.PharmiWeb.comConcept Life Sciences and OpenBench Launch Drug Discovery PartnershipConcept Life Sciences has partnered with OpenBench to expand access to success-based drug discovery services for early-stage biotechnology companies. The collaboration combines Concept Life Sciences' integrated CRO expertise with OpenBench's AI-enabled virtual screening platform to help accelerate the identification of novel drug candidates while reducing upfront costs for biotech innovators. Both companies aim to address growing industry demand for more flexible and efficient approaches to preclinical drug discovery.GlobeNewswireConcept Life Sciences Partners with OpenBench to Deliver Success-Based Drug Discovery Services for Early-Stage BiotechConcept Life Sciences and OpenBench announced a strategic partnership to accelerate drug discovery for biotech companies through a success-based fee model. OpenBench screens billions of compounds virtually and funds discovery activities, while Concept provides validation and development capabilities. The partnership aims to reduce costs and risks in early-stage biotech R&D.BioSpaceConcept Life Sciences Partners with OpenBench to Deliver Success-Based Drug Discovery Services for Early-Stage BiotechConcept Life Sciences and OpenBench announced a partnership to deliver success-based drug discovery services for early-stage biotech. OpenBench's AI platform virtually screens trillions of compounds, with fees paid only on validated hits, while Concept Life Sciences provides in-vitro testing and validation. The partnership aims to reduce upfront cost and risk, enabling hit series in as little as six months.Investing.comEarnings call transcript: Brii Biosciences reports strong cash position in H2 2025 By Investing.comBrii Biosciences Ltd held its H2 2025 earnings call reporting revenue of CNY 18.6 million, up from zero in 2024, driven primarily by an upfront payment from a licensing agreement with Joincare Group for soralimixin. The company maintained strong cash reserves of CNY 1,941 million to support operations beyond 2028, while reducing R&D expenses by 14.8% to CNY 212.9 million through cost control measures. Brii Bio is advancing its HBV functional cure program with three Phase 2b studies (ENSURE, ENRICH, ENHANCE) fully enrolled, expecting results in the second half of 2026, while also expanding discovery capabilities through internal labs in Beijing and Shanghai and a collaboration with AI drug discovery company OpenBench.PR NewswireBrii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial ResultsBrii Biosciences reported full year 2025 financial results showing a 56.3% reduction in net loss to RMB224.1 million, driven by lower operating expenses and reduced non-operating losses, alongside R&D expenses decreasing 14.8% to RMB212.9 million. The company maintained a strong cash position of US$276.1 million as of December 31, 2025, while advancing its late-stage hepatitis B virus (HBV) functional cure programs with Phase 2b ENSURE, ENRICH, and ENHANCE studies now fully enrolled and data expected in the second half of 2026. Brii Bio also expanded its discovery capabilities by establishing integrated laboratories in Beijing and Shanghai, announced a strategic out-licensing partnership with Joincare Group for soralimixin in Greater China, and entered a collaboration with OpenBench to leverage AI for discovery efforts.